Q3 Earnings Estimate for REGN Issued By Leerink Partnrs

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for Regeneron Pharmaceuticals in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $8.33 for the quarter, down from their previous forecast of $8.77. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q4 2025 earnings at $8.44 EPS, FY2025 earnings at $29.95 EPS and FY2026 earnings at $31.25 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $9.55 earnings per share.

REGN has been the topic of several other research reports. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. Finally, Bank of America lowered their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $822.58.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $9.64 during mid-day trading on Tuesday, reaching $547.75. 847,049 shares of the company traded hands, compared to its average volume of 907,358. The company has a market capitalization of $59.14 billion, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm's fifty day moving average is $547.93 and its two-hundred day moving average is $623.60. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in REGN. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares in the last quarter. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $802,036,000. GAMMA Investing LLC raised its position in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $343,764,000. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.